£95m costs to be cut - 770 worldwide Jobs Lost - Profits down to £537m - view original
Smith & Nephew PLC | Reg No. 00324357 | SIC Code 3310 | HQ London | Tel 0207 4017646 | Turnover £2,466.5m | Employees 10172 | Locations 5 | 64 Company Alerts | 5 Subsidiary Alerts
Smith & Nephew, which employs 11,000 people worldwide including 1,200 in the UK, is to save £95m in costs over the next two years by cutting around 770 administrative jobs.
06 Feb 2012
7,300 job losses - 2% fall in revenues - competitive pressures - view original
AstraZeneca PLC | Reg No. 02723534 | SIC Code 2441 | HQ London | Tel 0207 604 8000 | Turnover £20,209.6m | Employees 66600 | Locations 22 | 151 Company Alerts | 221 Subsidiary Alerts
Job Gains / Losses: 7300 Jobs Lost Sales: 7300 Jobs Lost Business Performance: 7300 Jobs Lost National: 7300 National Jobs Lost Chemicals, Pharm & Med : 7300 Jobs Lost Public Sector Suppliers: 7300 Jobs Lost
AstraZeneca is reducing headcount by 7,300 across its operations after revenue fell 2% to £22.2bn. Revenue in Western Europe fell 11% due to increased competition from generic drugs. It is not known which sites will be affected by the job cuts. The restructuring is expected to reduce costs and increase flexibility in functional areas.
06 Feb 2012
Revenue down 2% - Profit down 4% - 61700 Employees - view original
AstraZeneca PLC | Reg No. 02723534 | SIC Code 2441 | HQ London | Tel 0207 604 8000 | Turnover £20,209.6m | Employees 66600 | Locations 22 | 151 Company Alerts | 221 Subsidiary Alerts
AstraZeneca reorted revenue for the full year was down 2% at constant exchange rates at $33,591 million. Strong double-digit sales growth for Crestor, Seroquel XR and Symbicort; Emerging Markets revenue increased by 10%. Revenue performance reflects the loss of nearly $2 billion of revenue from generic competition, as well as a further $1 billion lost to the impact of government price interventions. David Brennan is Chief Executive Officer
03 Feb 2012
New product launched with partner - Contract extended worth £300,000 - view original
Byotrol Plc | Reg No. 05352525 | SIC Code 2420 | HQ North West | Tel 01925 742 000 | Turnover £1.9m | Employees 19 | Locations 4 | 19 Company Alerts
Byotrol plc, the developer of anti microbial hygiene technologies, and partner Rentokil Initial Plc, have formally launched the UltraProtect range, powered by Byotrol, under a contract announced in July 2011. UltraProtect is a range of hand and surface sanitising products for commercial and public use, featuring a gel hand sanitiser, a foam hand sanitiser, and handy packs of hand and surface wipes. In addition, Byotrol has agreed terms for a six month extension of the Joint Development Agreement ('JDA') with their Fortune 150 partner company, for which Byotrol Consumer Products Limited will receive $300,000. Gary Millar is the Chief Executive of Byotrol Plc.
03 Feb 2012
Profits increased to £322,000 - improved product lines
02 Feb 2012
Lease taken on warehouse - potential new jobs
31 Jan 2012
Changes to Board - New Chairs appointed - Non-Executive Directors appointed and step down
31 Jan 2012
Revenue up 10% - Underlying Revenue up 11% - 4300 Employees
27 Jan 2012
Business expansion - Sales rise by 4.1% - Seven new products launched
27 Jan 2012
Revenue £21.6m - Earnings above expectation - Further gowth expected
27 Jan 2012
Half Yearly Report - Revenue up 10% to £414m, Operating Profit down 12.8% to £40.1m
26 Jan 2012
Research and development contract - potential new jobs
26 Jan 2012
£20m gas plant underway - 40 new jobs
26 Jan 2012
Business expansion - Jobs created - Approval in USA
24 Jan 2012
Profit falls 17% - restructuring - Job lossses in health care division
23 Jan 2012
Surgical Innovations Group Plc - Trading Statement
20 Jan 2012
3 new Welsh sites - 1 site closed - Business restructuring
20 Jan 2012
Sales up 4.1% - Group revenue rises 14.1%
19 Jan 2012
Extension to Heanor fctory - potential new jobs
18 Jan 2012
Expansion plans - new premises - potential new jobs
17 Jan 2012
20 jobs lost - Decline in sales
17 Jan 2012
New Yorkshire premises - £437k loan
16 Jan 2012
Company Expansion - £9m Investment - £1.6m Grant
16 Jan 2012
Hydrodec Group Plc - Trading Update
16 Jan 2012
Alliance Pharma Plc - Pre-Close Trading Update
15 Jan 2012
Awarded share of £1.8m funding - product development
15 Jan 2012
Skincare laboratory opened - cutaneous biology services
15 Jan 2012
Profit warning
13 Jan 2012
Trading in line with Expectations
13 Jan 2012
Revenue £3m - Loss for year expected - New Commercial Director
12 Jan 2012
£1.46 million Research and Development grant received - 25 new jobs
The chemicals, pharmaceuticals, biosciences and medical supplies sector is one of the most dynamic areas of the UK manufacturing economy and builds on Britain's traditional strengths in breakthrough scientific advance and technology innovation. It has world leadership in many fields and, in the contexts of globalisation and the gathering industrial strength and low costs base of major developing countries, continues to provide the UK with a competitive edge in high value-added knowledge based products.